The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

Published:2019-07-25 Issue:13 Volume:79 Page:1375-1394
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Taieb Julien^ORCID,Jung Andreas,Sartore-Bianchi Andrea^ORCID,Peeters Marc,Seligmann Jenny,Zaanan Aziz,Burdon Peter^ORCID,Montagut Clara,Laurent-Puig Pierre^ORCID

Funder

Amgen (Europe) GmbH

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01165-2.pdf

Reference185 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Patil H, Saxena SG, Barrow CJ, Kanwar JR, Kapat A, Kanwar RK. Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discov Today. 2017;22:111–9.

3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.

4. Boeckx N, Janssens K, Van Camp G, Rasschaert M, Papadimitriou K, Peeters M, et al. The predictive value of primary tumor location in patients with metastatic colorectal cancer: a systematic review. Crit Rev Oncol Hematol. 2018;121:1–10.

5. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer;Digestive and Liver Disease;2024-08

2. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts;European Journal of Cancer;2024-07

3. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials;Annals of Oncology;2023-11

4. Perspective Chapter: Topoisomerase 1 and Colo Rectal Carcinoma;DNA Replication - Epigenetic Mechanisms and Gene Therapy Applications;2023-09-06

5. Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial;Frontiers in Oncology;2023-05-03